Interstitial Lung Disease Treatment Drugs, Pipeline Insights Report 2024

DelveInsight's, "Interstitial Lung Diseases Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Interstitial Lung Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Interstitial Lung Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Interstitial Lung Disease Pipeline Report
• August 2024:- United Therapeutics- Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with IPF over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.
• August 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
• DelveInsight's interstitial lung disease Pipeline report depicts a robust space with 120+ active players working to develop 120 + pipeline therapies for interstitial lung disease treatment.
• The leading Interstitial Lung Disease Companies working in the market include Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
• Promising Interstitial Lung Disease Therapies in the various stages of development include AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.

Stay ahead with the most recent pipeline outlook for Interstitial Lung Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Interstitial Lung Disease Treatment Drugs- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Emerging Drugs Profile
• DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body's ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein's sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.
• LYT-100: PureTech
LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.
• BMS-986278: Bristol-Myers Squibb
BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation

Explore groundbreaking therapies and clinical trials in the Interstitial Lung Disease Pipeline. Access DelveInsight's detailed report now! @ New Interstitial Lung Disease Drugs- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous

Interstitial Lung Disease Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Interstitial Lung Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Interstitial Lung Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Interstitial Lung Disease Pipeline Report
• Coverage- Global
• Interstitial Lung Disease Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
• Interstitial Lung Disease Therapies- AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
• Interstitial Lung Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Interstitial Lung Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Interstitial Lung Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Interstitial Lung Disease Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Interstitial Lung Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Interstitial Lung Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RO-0220912: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Daratumumab: Janssen Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BGB 16673: BeiGene
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Interstitial Lung Disease Key Companies
21. Interstitial Lung Disease Key Products
22. Interstitial Lung Disease- Unmet Needs
23. Interstitial Lung Disease- Market Drivers and Barriers
24. Interstitial Lung Disease- Future Perspectives and Conclusion
25. Interstitial Lung Disease Analyst Views
26. Interstitial Lung Disease Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
info@delveinsight.com
+91-9650213330

This release was published on openPR.